Novo Nordisk lowered its full-year guidance as copycat versions of its blockbuster weight-loss and diabetes drugs in the U.S.

Datadog's Q1 results show moderate growth, but AI-native contributions are insufficient to significantly boost revenue, leading to a downgrade to Hold. Management's strategy involves heavy investment ...